Perigon Wealth Management LLC Has $16.80 Million Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Perigon Wealth Management LLC lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 29,902 shares of the medical research company’s stock after selling 99 shares during the period. Perigon Wealth Management LLC’s holdings in Thermo Fisher Scientific were worth $16,796,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in TMO. Patrick M Sweeney & Associates Inc. increased its position in Thermo Fisher Scientific by 2.1% during the fourth quarter. Patrick M Sweeney & Associates Inc. now owns 1,066 shares of the medical research company’s stock worth $555,000 after acquiring an additional 22 shares during the period. Curbstone Financial Management Corp acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $685,000. Revolve Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 4.2% in the fourth quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company’s stock valued at $255,000 after buying an additional 20 shares in the last quarter. YHB Investment Advisors Inc. grew its position in Thermo Fisher Scientific by 0.4% during the fourth quarter. YHB Investment Advisors Inc. now owns 46,450 shares of the medical research company’s stock worth $24,165,000 after buying an additional 200 shares in the last quarter. Finally, Nilsine Partners LLC raised its holdings in Thermo Fisher Scientific by 4.6% in the 4th quarter. Nilsine Partners LLC now owns 10,665 shares of the medical research company’s stock valued at $5,548,000 after acquiring an additional 473 shares in the last quarter. 89.23% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Morgan Stanley decreased their price target on Thermo Fisher Scientific from $670.00 to $647.00 and set an “overweight” rating on the stock in a research report on Monday, January 13th. StockNews.com raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research report on Friday, January 10th. Robert W. Baird cut their target price on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Redburn Atlantic began coverage on Thermo Fisher Scientific in a report on Monday, October 14th. They set a “buy” rating and a $680.00 price target for the company. Four investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has a consensus rating of “Moderate Buy” and a consensus price target of $648.95.

Thermo Fisher Scientific Stock Up 1.5 %

Thermo Fisher Scientific stock opened at $583.43 on Tuesday. The firm has a market cap of $223.16 billion, a price-to-earnings ratio of 36.58, a PEG ratio of 3.82 and a beta of 0.76. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.26 and a current ratio of 1.63. The firm has a 50 day moving average price of $533.60 and a two-hundred day moving average price of $569.81.

Thermo Fisher Scientific Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, January 15th. Shareholders of record on Friday, December 13th were given a dividend of $0.39 per share. The ex-dividend date was Friday, December 13th. This represents a $1.56 dividend on an annualized basis and a yield of 0.27%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 9.78%.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock repurchase plan on Friday, November 15th that authorizes the company to buyback $4.00 billion in outstanding shares. This buyback authorization authorizes the medical research company to reacquire up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its shares are undervalued.

Insider Activity

In other news, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $558.12, for a total transaction of $5,581,200.00. Following the completion of the sale, the chief executive officer now owns 33,608 shares of the company’s stock, valued at $18,757,296.96. This trade represents a 22.93 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Insiders have sold 34,850 shares of company stock valued at $19,123,197 in the last ninety days. 0.34% of the stock is owned by company insiders.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.